Inhaled Nitric Oxide Market by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global inhaled nitric oxide market was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020-2027.
Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide is a gas available in 100 ppm and 800 ppm concentrations depending on the treatment. Further, clinical trials evaluating the use of inhaled nitric oxide for numerous indications are ongoing. The potential therapeutic role of inhaled nitric oxide in adults remains uncertain at this time and FDA-approved indications are restricted to pediatric practice.
As nitric oxide exists as a gas, it can be easily administered for inhalation and is classified in the pharmacotherapeutic group. It relaxes the vascular smooth muscle by activating guanylate cyclase and increases intracellular levels of cGMP, which then leads to vasodilation and increased oxygenation. Nitric oxide is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
The market growth is driven due to factors such as increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, rise in number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, high cost of treatment and strict government regulations for various applications hamper the market growth.
Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global market in the near future.
The global inhaled nitric oxide market is segmented into application, and region. By applications, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific and rest of world. Asia Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia-Pacific market.
The inhaled nitric oxide market provides extensive competitive analysis and profiles of key market players, such as Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.
KEY BENEFITS FOR STAKEHOLDERS
By Application
Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide is a gas available in 100 ppm and 800 ppm concentrations depending on the treatment. Further, clinical trials evaluating the use of inhaled nitric oxide for numerous indications are ongoing. The potential therapeutic role of inhaled nitric oxide in adults remains uncertain at this time and FDA-approved indications are restricted to pediatric practice.
As nitric oxide exists as a gas, it can be easily administered for inhalation and is classified in the pharmacotherapeutic group. It relaxes the vascular smooth muscle by activating guanylate cyclase and increases intracellular levels of cGMP, which then leads to vasodilation and increased oxygenation. Nitric oxide is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
The market growth is driven due to factors such as increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, rise in number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, high cost of treatment and strict government regulations for various applications hamper the market growth.
Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global market in the near future.
The global inhaled nitric oxide market is segmented into application, and region. By applications, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific and rest of world. Asia Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia-Pacific market.
The inhaled nitric oxide market provides extensive competitive analysis and profiles of key market players, such as Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify the prevailing opportunities.
- The inhaled nitric oxide market size and estimations are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on region assists to understand the regional market and the strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
By Application
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others (Tuberculosis Treatment)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- Australia
- Rest of World
- Air Liquide S.A
- Bellerophon Therapeutics, Inc.
- BOC Healthcare
- Beyond Air, Inc.
- Halma Plc
- Linde Plc
- Mallinckrodt plc
- Novoteris, LLC
- VERO Biotech LLC
- Nu-Med Plus
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in demand from healthcare sector
3.5.1.2.Increase in chronic diseases
3.5.2.Restraints
3.5.2.1.High cost of treatment
3.5.2.2.Strict application norms
3.5.3.Opportunity
3.5.3.1.Ongoing R&D activities leading to new application areas in healthcare industry
3.6.Impact Analysis of COVID-19 on inhaled nitric oxide market
3.7.Inhaled nitric oxide concentrations
3.8.Clinical Trials – From 2010 to 2022
CHAPTER 4:INHALED NITRIC OXIDE MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Neonatal respiratory treatment
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Chronic obstructive pulmonary disease (COPD)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Acute respiratory distress syndrome (ARDS)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:INHALED NITRIC OXIDE MARKET, BY REGION
5.1.Overview
5.1.1.Market size and forecast
5.2.North America
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.North America market size and forecast, by country
5.2.2.1.U.S.
5.2.2.1.1.U.S. market size and forecast, by application
5.2.2.2.Canada
5.2.2.2.1.Canada market size and forecast, by application
5.2.2.3.Mexico
5.2.2.3.1.Mexico market size and forecast, by application
5.2.3.North America market size and forecast, by application
5.3.Europe
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Europe inhaled nitric oxide market, by country
5.3.2.1.Germany
5.3.2.1.1.Germany market size and forecast, by application
5.3.2.2.France
5.3.2.2.1.France market size and forecast, by application
5.3.2.3.UK
5.3.2.3.1.UK market size and forecast, by application
5.3.2.4.Italy
5.3.2.4.1.Italy market size and forecast, by application
5.3.2.5.Rest of Europe
5.3.2.5.1.Rest of Europe market size and forecast, by application
5.3.3.Europe market size and forecast, by application
5.4.Asia-Pacific
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Asia-Pacific market size and forecast, by country
5.4.2.1.Japan
5.4.2.1.1.Japan market size and forecast, by application
5.4.2.2.Australia
5.4.2.2.1.Australia market size and forecast, by application
5.4.2.3.Rest of world
5.4.2.3.1.Rest of world market size and forecast, by application
5.4.3.Asia-Pacific market size and forecast, by application
CHAPTER 6:COMPANY PROFILES
6.1.AIR LIQUIDE S.A.
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product Portfolio
6.1.5.Business performance
6.2.BELLEROPHON THERAPEUTICS, INC.
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Product portfolio
6.2.4.Key strategic moves and developments
6.3.BOC HEALTHCARE
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Product portfolio
6.4.BEYOND AIR, INC.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Product Portfolio
6.4.4.Business performance
6.4.5.Key strategic moves and developments
6.5.HALMA PLC
6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio
6.5.5.Business performance
6.6.LINDE PLC (PRAXAIR, INC.)
6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Product Portfolio
6.6.4.Business performance
6.6.5.Key strategic moves and developments
6.7.MALLINCKRODT PLC
6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio
6.7.5.Business performance
6.7.6.Key strategic moves and developments
6.8.NOVOTERIS, LLC
6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Product Portfolio
6.9.VERO BIOTECH LLC
6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Product portfolio
6.9.4.Key strategic moves and developments
6.10.NU-MED PLUS
6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product Portfolio
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in demand from healthcare sector
3.5.1.2.Increase in chronic diseases
3.5.2.Restraints
3.5.2.1.High cost of treatment
3.5.2.2.Strict application norms
3.5.3.Opportunity
3.5.3.1.Ongoing R&D activities leading to new application areas in healthcare industry
3.6.Impact Analysis of COVID-19 on inhaled nitric oxide market
3.7.Inhaled nitric oxide concentrations
3.8.Clinical Trials – From 2010 to 2022
CHAPTER 4:INHALED NITRIC OXIDE MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Neonatal respiratory treatment
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Chronic obstructive pulmonary disease (COPD)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Acute respiratory distress syndrome (ARDS)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:INHALED NITRIC OXIDE MARKET, BY REGION
5.1.Overview
5.1.1.Market size and forecast
5.2.North America
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.North America market size and forecast, by country
5.2.2.1.U.S.
5.2.2.1.1.U.S. market size and forecast, by application
5.2.2.2.Canada
5.2.2.2.1.Canada market size and forecast, by application
5.2.2.3.Mexico
5.2.2.3.1.Mexico market size and forecast, by application
5.2.3.North America market size and forecast, by application
5.3.Europe
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Europe inhaled nitric oxide market, by country
5.3.2.1.Germany
5.3.2.1.1.Germany market size and forecast, by application
5.3.2.2.France
5.3.2.2.1.France market size and forecast, by application
5.3.2.3.UK
5.3.2.3.1.UK market size and forecast, by application
5.3.2.4.Italy
5.3.2.4.1.Italy market size and forecast, by application
5.3.2.5.Rest of Europe
5.3.2.5.1.Rest of Europe market size and forecast, by application
5.3.3.Europe market size and forecast, by application
5.4.Asia-Pacific
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Asia-Pacific market size and forecast, by country
5.4.2.1.Japan
5.4.2.1.1.Japan market size and forecast, by application
5.4.2.2.Australia
5.4.2.2.1.Australia market size and forecast, by application
5.4.2.3.Rest of world
5.4.2.3.1.Rest of world market size and forecast, by application
5.4.3.Asia-Pacific market size and forecast, by application
CHAPTER 6:COMPANY PROFILES
6.1.AIR LIQUIDE S.A.
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product Portfolio
6.1.5.Business performance
6.2.BELLEROPHON THERAPEUTICS, INC.
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Product portfolio
6.2.4.Key strategic moves and developments
6.3.BOC HEALTHCARE
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Product portfolio
6.4.BEYOND AIR, INC.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Product Portfolio
6.4.4.Business performance
6.4.5.Key strategic moves and developments
6.5.HALMA PLC
6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio
6.5.5.Business performance
6.6.LINDE PLC (PRAXAIR, INC.)
6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Product Portfolio
6.6.4.Business performance
6.6.5.Key strategic moves and developments
6.7.MALLINCKRODT PLC
6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio
6.7.5.Business performance
6.7.6.Key strategic moves and developments
6.8.NOVOTERIS, LLC
6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Product Portfolio
6.9.VERO BIOTECH LLC
6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Product portfolio
6.9.4.Key strategic moves and developments
6.10.NU-MED PLUS
6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product Portfolio
LIST OF TABLES
TABLE 01.GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 02.INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2019-2027 ($MILLION)
TABLE 03.INHALED NITRIC OXIDE MARKET FOR COPD, BY REGION, 2019-2027 ($MILLION)
TABLE 04.INHALED NITRIC OXIDE MARKET FOR ARDS, BY REGION, 2019-2027 ($MILLION)
TABLE 05.INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
TABLE 06.INHALED NITRIC OXIDE MARKET, BY REGION, 2019–2027($MILLION)
TABLE 07.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 08.U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 09.CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 10.MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 11.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 12.EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 13.GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 14.FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 15.UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 16.ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 17.REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 18.EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 19.ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 20.JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 21.AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 22.REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 23.ASIA-PACIFIC AND REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 24.AIR LIQUIDE: COMPANY SNAPSHOT
TABLE 25.AIR LIQUIDE: OPERATING SEGMENT
TABLE 26.AIR LIQUIDE: PRODUCT PORTFOLIO
TABLE 27.BELLEROPHON THERAPEUTICS: COMPANY SNAPSHOT
TABLE 28.BELLEROPHON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 29.BOC HEALTHCARE: COMPANY SNAPSHOT
TABLE 30.BOC HEALTHCARE: PRODUCT PORTFOLIO
TABLE 31.BEYOND AIR: COMPANY SNAPSHOT
TABLE 32.BEYOND AIR: PRODUCT PORTFOLIO
TABLE 33.HALMA: COMPANY SNAPSHOT
TABLE 34.HALMA: BUSINESS SEGMENTS
TABLE 35.HALMA: PRODUCT PORTFOLIO
TABLE 36.LINDE: COMPANY SNAPSHOT
TABLE 37.LINDE: PRODUCT PORTFOLIO
TABLE 38.MALLINCKRODT: COMPANY SNAPSHOT
TABLE 39.MALLINCKRODT: BUSINESS SEGMENTS
TABLE 40.MALLINCKRODT: PRODUCT PORTFOLIO
TABLE 41.NOVOTERIS: SNAPSHOT
TABLE 42.NOVOTERIS: PRODUCT PORTFOLIO
TABLE 43.VERO BIOTECH: COMPANY SNAPSHOT
TABLE 44.VERO BIOTECH: PRODUCT PORTFOLIO
TABLE 45.NU-MED PLUS: COMPANY SNAPSHOT
TABLE 46.NU-MED PLUS: PRODUCT PORTFOLIO
TABLE 01.GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 02.INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2019-2027 ($MILLION)
TABLE 03.INHALED NITRIC OXIDE MARKET FOR COPD, BY REGION, 2019-2027 ($MILLION)
TABLE 04.INHALED NITRIC OXIDE MARKET FOR ARDS, BY REGION, 2019-2027 ($MILLION)
TABLE 05.INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
TABLE 06.INHALED NITRIC OXIDE MARKET, BY REGION, 2019–2027($MILLION)
TABLE 07.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 08.U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 09.CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 10.MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 11.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 12.EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 13.GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 14.FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 15.UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 16.ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 17.REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 18.EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 19.ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 20.JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 21.AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 22.REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 23.ASIA-PACIFIC AND REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 24.AIR LIQUIDE: COMPANY SNAPSHOT
TABLE 25.AIR LIQUIDE: OPERATING SEGMENT
TABLE 26.AIR LIQUIDE: PRODUCT PORTFOLIO
TABLE 27.BELLEROPHON THERAPEUTICS: COMPANY SNAPSHOT
TABLE 28.BELLEROPHON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 29.BOC HEALTHCARE: COMPANY SNAPSHOT
TABLE 30.BOC HEALTHCARE: PRODUCT PORTFOLIO
TABLE 31.BEYOND AIR: COMPANY SNAPSHOT
TABLE 32.BEYOND AIR: PRODUCT PORTFOLIO
TABLE 33.HALMA: COMPANY SNAPSHOT
TABLE 34.HALMA: BUSINESS SEGMENTS
TABLE 35.HALMA: PRODUCT PORTFOLIO
TABLE 36.LINDE: COMPANY SNAPSHOT
TABLE 37.LINDE: PRODUCT PORTFOLIO
TABLE 38.MALLINCKRODT: COMPANY SNAPSHOT
TABLE 39.MALLINCKRODT: BUSINESS SEGMENTS
TABLE 40.MALLINCKRODT: PRODUCT PORTFOLIO
TABLE 41.NOVOTERIS: SNAPSHOT
TABLE 42.NOVOTERIS: PRODUCT PORTFOLIO
TABLE 43.VERO BIOTECH: COMPANY SNAPSHOT
TABLE 44.VERO BIOTECH: PRODUCT PORTFOLIO
TABLE 45.NU-MED PLUS: COMPANY SNAPSHOT
TABLE 46.NU-MED PLUS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.INHALED NITRIC OXIDE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2020*
FIGURE 06.TOP PLAYER POSITIONING
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.LOW THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 13.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR COPD, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ARDS , 2019 & 2027 (%)
FIGURE 16.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS , 2019 & 2027 (%)
FIGURE 17.AIR LIQUIDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.AIR LIQUIDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 19.AIR LIQUIDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20.BEYOND AIR: NET SALES, 2019-2020 ($MILLION)
FIGURE 21.HALMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.HALMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.HALMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24.LINDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.LINDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.LINDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 27.MALLINCKRODT: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MALLINCKRODT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 29.MALLINCKRODT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 01.INHALED NITRIC OXIDE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2020*
FIGURE 06.TOP PLAYER POSITIONING
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.LOW THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 13.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR COPD, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ARDS , 2019 & 2027 (%)
FIGURE 16.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS , 2019 & 2027 (%)
FIGURE 17.AIR LIQUIDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.AIR LIQUIDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 19.AIR LIQUIDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20.BEYOND AIR: NET SALES, 2019-2020 ($MILLION)
FIGURE 21.HALMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.HALMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.HALMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24.LINDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.LINDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.LINDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 27.MALLINCKRODT: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MALLINCKRODT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 29.MALLINCKRODT: REVENUE SHARE BY REGION, 2019 (%)
